+44 (0) 20 7549 9987 | USA callers: +1 212 220 8419

Contact Us Now

Breast Cancer Drugs Market To Be Worth $19.96bn In 2020, New Visiongain Analysis Predicts

10 September 2018
Pharma

A new visiongain report forecasts that the global breast cancer drugs market will generate $19.96 billion in 2020. That revenue forecast and many others appear in Breast Cancer Drugs Market 2016-2026: Revenue Forecasts for Monoclonal Antibodies, Hormones, Chemotherapy, Kinase Inhibitors and Other Pharmaceuticals, published in March 2016. Visiongain is a business information publisher and consultancy based in London, UK.

Arshad Ahad, a senior pharmaceutical industry analyst in visiongain, said: “Breast cancer is the second most common cancer in the world, and by far the most common cancer among women. With the prevalence of the disease set to increase, a strong pipeline waiting to be launched, and the rising use of combination therapies to benefit both patients and manufacturers, we expect strong growth for this lucrative market.

“However, the breast cancer drugs market will also have to face patent expiries for various leading therapies during the forecast period and the looming threat of generic and biosimilar erosion, amongst other difficult challenges. As such, 2016-2026 is a crucial period for this market, one which will determine its long term future.”

Visiongain’s new analysis provides revenue forecasts for the global breast cancer drugs market from 2016 to 2026.

That study also gives revenue forecasts, specifically for the breast cancer indication, for nine leading drugs from 2016 to 2026:

• Herceptin (trastuzumab), Roche
• Perjeta (pertuzumab), Roche
• Afinitor (everolimus), Novartis
• Faslodex (fulvestrant), AstraZeneca
• Ibrance (palbociclib), Pfizer
• Avastin (bevacizumab), Roche
• Kadcyla (ado-trastuzumab emtansine), Roche
• Femara (letrozole), Novartis
• Abraxane (paclitaxel Protein-Bound), Celgene.

That investigation also provides overall forecasts for two classes of biosimilar: trastuzumab and bevacizumab.

The report also divides the overall market into its main therapeutic segments, showing revenue forecasts from 2016 to 2026 for these four submarkets:

• Monoclonal antibodies (mAbs)
• Chemotherapy and hormone therapy
• Kinase inhibitors
• Other medicines.
That work also assesses the current status of 18 of the most promising candidates in research and development. It also shows interviews with two companies. In addition, visiongain’s study provides revenue forecasts for 11 national breast cancer drug markets:

• The United States
• Japan
• Germany, France, Italy, the United Kingdom and Spain (EU5 countries)
• Brazil, Russia, India and China (BRIC group).

Breast Cancer Drugs Market 2016-2026: Revenue Forecasts for Monoclonal Antibodies, Hormones, Chemotherapy, Kinase Inhibitors and Other Pharmaceuticals adds to visiongain’s analysis on industries and markets in healthcare. Together those studies cover pharmaceuticals, biotechnology, outsourced services, diagnostics and medical devices.

Recent News

Cell & Gene Therapy Cold Chain Logistics Market

The global Cell and Gene Therapy Cold Chain Logistics market is projected to grow at a CAGR of 15.5% by 2034

19 June 2024

Read

Cancer Immunotherapy Market

The global Cancer Immunotherapy market is projected to grow at a CAGR of 12.6% by 2034

11 June 2024

Read

Biological Safety Testing Market

The global Biological Safety Testing market is projected to grow at a CAGR of 12.6% by 2034

11 June 2024

Read

CAR-T Therapy Market

The global CAR-T Therapy market is projected to grow at a CAGR of 35.9% by 2034

11 June 2024

Read